|1.||Pastan, Ira: 4 articles (06/2011 - 11/2006)|
|2.||Kreitman, Robert J: 3 articles (06/2011 - 02/2009)|
|3.||Wilson, Wyndham H: 1 article (06/2011)|
|4.||Arons, Evgeny: 1 article (06/2011)|
|5.||Fitzgerald, David J P: 1 article (06/2011)|
|6.||Stetler-Stevenson, Maryalice: 1 article (06/2011)|
|7.||Lee, Byungkook: 1 article (04/2011)|
|8.||Weldon, John E: 1 article (04/2011)|
|9.||Xiang, Laiman: 1 article (04/2011)|
|10.||Beers, Richard: 1 article (04/2011)|
02/01/2009 - "In vivo, when JD38 tumor-bearing animals were treated with CAT-8015 at doses > or =75 microg/kg at 48-hour intervals for a total of three doses, a rapid reduction in tumor volume and in some cases complete remission in tumor growth was observed. "
02/01/2009 - "The biological activity of CAT-8015 was examined in vitro using B-cell tumor lines and in vivo in a JD38-based s.c. "
11/01/2006 - "A single intravitreal injection of immunotoxin HA22 after the establishment of the PIOL resulted in complete regression of the tumor. "
|2.||Hematologic Neoplasms (Hematological Malignancy)
|3.||Hairy Cell Leukemia
04/05/2011 - "A recombinant immunotoxin (HA22, CAT8015, moxetumomab pasudotox) composed of an anti-CD22 antibody variable fragment fused to PE38, a 38-kDa portion of Pseudomonas exotoxin A, has produced many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can be given, but has much less activity when antibodies develop. "